Adeno-associated virus capsid protein, adeno-associated virus comprising same and use

By inserting the RGD short peptide GRGDSP into the capsids of AAV2, AAV6, and AAV9, the problems of low infection efficiency and poor targeting of AAV in brain tumor treatment are solved, efficient delivery of brain tissue is achieved, and more stable Treatment plan.

WO2024234803A1PCT designated stage expired Publication Date: 2024-11-21HANGZHOU XINCHANG GENE THERAPEUTICS INC

Patent Information

Application Number
PCT/CN2024/081199
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-15
Filing Date
2024-03-12
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The existing adeno-associated virus (AAV) has problems with low infection efficiency and poor targeting in brain tumor treatment, especially the inability to cross the blood-brain barrier, which limits the possibility of blood administration, and the existing AAV capsid The effect of the transformation method is unstable and depends on a variety of factors.

Method used

By inserting the RGD short peptide GRGDSP derived from human fibromin into the capsid protein of AAV2, AAV6, AAV9, especially into specific amino acid sites such as G453 and R588 sites of AAV2, G454 and S588 sites of AAV6, G454 and S588 sites of AAV6 The G455 and G588 sites of AAV9 are transformed into novel AAV capsids that improve cell infection efficiency and brain tissue targeting.

Benefits of technology

It has achieved good targeting of brain tissue and improved in vivo and in vitro cell infection efficiency, and provided a more suitable gene drug delivery vehicle for the treatment of brain tumors and other brain diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024081199_21112024_PF_FP_ABST
    Figure CN2024081199_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are an adeno-associated virus capsid protein, an adeno-associated virus comprising same and the use. Specifically, provided is an adeno-associated virus capsid protein comprising a targeting peptide, wherein the targeting peptide comprises one or more of the following sequences: an amino acid sequence as shown in SEQ ID NO: 23; an amino acid sequence having at least 80% identity to the amino acid sequence as shown in SEQ ID NO: 23, etc. The adeno-associated virus capsid protein and the adeno-associated virus comprising same have good producibility, have improved cell infection efficiency both in vivo and in vitro compared with a wild-type adeno-associated virus, have good targeting of brain tissue, and can be used as delivery carriers for treating brain tumors and other brain-associated diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Adeno-associated virus capsid protein, adeno-associated virus containing same and application thereof

[0001] Priority and related applications

[0002] The present disclosure claims priority to Chinese patent application No. 202310560310.8, filed on May 15, 2023, entitled “Adeno-associated virus capsid protein, adeno-associated virus containing the same and applications thereof”, the entire contents of which, including the appendix, are incorporated into the present disclosure by reference. Technical Field

[0003] The present disclosure relates to the technical field of viral vectors, and in particular to an adeno-associated virus capsid protein, an adeno-associated virus containing the same, and applications thereof. Background Art

[0004] Malignant brain tumors are often associated with a poor prognosis. Clinical treatment options are very limited. Gene therapy has great potential for treating malignant brain tumors. 1 Adeno-associated virus (AAV) is widely used in in vivo gene therapy, but AAV has not yet been used in clinical treatment of tumors. 2,3 AAV tumor infection efficiency and targeting are important application bottlenecks.

[0005] The function of AAV is largely determined by the capsid. The capsid of AAV determines the tissue targeting, transfection efficiency and immune response of AAV. Capsid modification is currently an important means to improve the function of AAV. 4 .

[0006] Available routes of administration for brain tumor treatment include local intratumoral injection, vascular administration, and intracranial cerebrospinal fluid administration. The AAV type currently commonly used in brain tumor research is wild-type AAV2. The disadvantages of AAV2 include poor infectivity of brain tumor tissue in vivo, inability to cross the blood-brain barrier (BBB), and therefore inability to target brain tumors through blood administration. In addition, the infection efficiency and targeting of brain tissue after cerebrospinal fluid administration are poor. 3,5 Other AAV types available for brain tumor treatment include AAV6 and AAV9, but both have similar shortcomings to AAV2. 6 .

[0007] Inserting functionalized short peptides into AAV capsid is an important method for AAV capsid modification. 4Since most tumor cells highly express integrins, and the arginine-glycine-aspartic acid domain (RGD domain, RGD domain, or RGD peptide) is a key site for many ligand proteins that can bind to integrins, previous work has inserted short peptides with RGD domains into specific sites of the AAV capsid to increase the affinity of AAV for tumor cells. For example, the RGD peptide (QAGTFALRGDNPQG) was inserted into site 587 of AAV2. 7 , the RGD short peptide (CDCRGDCFC) was inserted into the 588 site of AAV2 8 .

[0008] Although theoretically AAV with RGD peptide may enhance the infection efficiency of tumor cells, it actually depends on many factors, such as the specific sequence of the inserted RGD peptide, the specific type of AAV, the capsid insertion site and the protein conformation after insertion. If used for tumor drug development, the practicality of this RGD-modified AAV also depends on the type of tumor cells, the microenvironment in which the tumor cells are located and the specific method of administration. For example, when the RGD peptide CDCRGDCFC is inserted into the 588 site of the AAV2 capsid, the new AAV has an enhanced affinity for tumor cells, but when the same peptide is inserted into the 453 site of the AAV2 capsid, the new AAV completely loses its ability to infect cells. 9 .

[0009] Summary of the Invention

[0010] Problems to be solved by the invention

[0011] To identify novel AAVs suitable for brain tumor treatment, the authors selected GRGDSP, a short RGD peptide derived from human fibronectin, and used genetic engineering techniques to insert it into the G453 and R588 sites of AAV2, the G454 and S588 sites of AAV6, and the G455 and G588 sites of AAV9. The authors conducted a comprehensive analysis and evaluation of the six newly generated AAV variants for their manufacturability, in vitro and in vivo cell infection efficiency, and brain tissue targeting. Finally, they identified several novel AAV capsids suitable for future gene therapy development.

[0012] Solutions for solving problems

[0013] In a first aspect of the present invention, an adeno-associated virus capsid protein is provided, which includes a targeting peptide, wherein the targeting peptide comprises one or more of the following sequences:

[0014] (i) the amino acid sequence set forth in SEQ ID NO: 23;

[0015] (ii) an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 23, and that has or partially has the function of the amino acid sequence of SEQ ID NO: 23;

[0016] (iii) an amino acid sequence in which one or more amino acid residues are added, substituted, deleted or inserted into the amino acid sequence of SEQ ID NO: 23, and which has or partially has the function of the amino acid sequence of SEQ ID NO: 23; or

[0017] (iv) an amino acid sequence encoded by a nucleotide sequence that hybridizes with a polynucleotide sequence encoding the amino acid sequence as shown in SEQ ID NO: 23 under stringent conditions, and the amino acid sequence has or partially has the function of the amino acid sequence as shown in SEQ ID NO: 23, wherein the stringent conditions are moderate stringency conditions, medium-high stringency conditions, high stringency conditions or very high stringency conditions.

[0018] In some embodiments, the adeno-associated virus is selected from one or more of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, rh.10, rh.39, rh.43, and rh.74.

[0019] In some preferred embodiments, the adeno-associated virus is selected from one or more of AAV2, AAV6 and AAV9.

[0020] In some embodiments, AAV2 includes AAV2 VP1, AAV2 VP2 and / or AAV2 VP3; and / or, AAV6 includes AAV6 VP1, AAV6 VP2 and / or AAV6 VP3; and / or, AAV9 includes AAV9 VP1, AAV9 VP2 and / or AAV9 VP3.

[0021] In some specific embodiments, the targeting peptide is inserted at position 453 of amino acid and / or position 588 of amino acid of AAV2 VP1, AAV2 VP2 and / or AAV2 VP3; and / or, the targeting peptide is inserted at position 454 of amino acid and / or position 588 of amino acid of AAV6 VP1, AAV6 VP2 and / or AAV6 VP3; and / or, the targeting peptide is inserted at position 455 of amino acid and / or position 588 of amino acid of AAV9 VP1, AAV9 VP2 and / or AAV9 VP3.

[0022] In some specific embodiments, the targeting peptide is inserted at position 453 of amino acid of AAV2 VP1, AAV2 VP2 and / or AAV2 VP3; and / or, the targeting peptide is inserted at position 454 of amino acid of AAV6 VP1, AAV6 VP2 and / or AAV6 VP3; and / or, the targeting peptide is inserted at position 588 of amino acid of AAV9 VP1, AAV9 VP2 and / or AAV9 VP3.

[0023] In the second aspect of the present invention, a polynucleotide is provided, which encodes the adeno-associated virus capsid protein described in the first aspect of the present invention.

[0024] In the third aspect of the present invention, an adeno-associated virus is provided, which comprises the adeno-associated virus capsid protein described in the first aspect of the present invention.

[0025] In some embodiments, the adeno-associated virus further comprises a transgene.

[0026] In some optional embodiments, the transgene is a therapeutic transgene, a preventive transgene, or a diagnostic transgene.

[0027] In a fourth aspect of the present invention, a transgene delivery vector is provided, which comprises the adeno-associated virus according to the third aspect of the present invention.

[0028] In a fifth aspect of the present invention, there is provided a pharmaceutical composition comprising:

[0029] (a) the adeno-associated virus of the third aspect of the present invention, or the transgene delivery vector of the fourth aspect of the present invention; and, optionally,

[0030] (b) a pharmaceutically acceptable carrier.

[0031] In the sixth aspect of the present invention, there is provided the use of the adeno-associated virus described in the third aspect of the present invention, the transgene delivery vector described in the fourth aspect of the present invention, or the pharmaceutical composition described in the fifth aspect of the present invention in the preparation of an agent for delivering a transgene to a cell.

[0032] In some embodiments, the cell is from a subject.

[0033] In some preferred embodiments, the subject is a mammalian subject.

[0034] In some more preferred embodiments, the subject is a human.

[0035] In some embodiments, the cells are from brain tissue.

[0036] In some embodiments, the subject suffers from a brain disease.

[0037] In some embodiments, the adeno-associated virus, the transgene delivery vector, or the pharmaceutical composition is administered to the subject one or more of intravenously, intraarterially, subcutaneously, intraperitoneally, intramuscularly, into the cerebrospinal fluid, into brain tissue, or into a tumor.

[0038] In some preferred embodiments, the adeno-associated virus, the transgene delivery vector, or the pharmaceutical composition is administered to the subject one or more of intravenously, intraarterially, intracerebral spinal fluid, intracerebral tissue, or intratumorally.

[0039] In a seventh aspect, the present invention provides use of the adeno-associated virus of the third aspect of the present invention, the transgene delivery vector of the fourth aspect of the present invention, or the pharmaceutical composition of the fifth aspect of the present invention in the preparation of a medicament for treating a disease.

[0040] In some preferred embodiments, the disease comprises a brain disease.

[0041] Effects of the Invention

[0042] The adeno-associated virus capsid protein and the adeno-associated virus containing the same provided by the present invention have good manufacturability and, compared with wild-type adeno-associated virus, have improved in vivo and in vitro cell infection efficiency and good targeting to brain tissue, and can be used as a delivery vector for the treatment of brain tumors and other brain-related diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1: AAV capsid model and modification sites.

[0044] The left side shows a three-dimensional model of the AAV capsid and one of the capsid protein monomers (VP3). The right side is a partial enlargement of the left side to show the corresponding position of the modification site in the VP3 monomer. An AAV particle is composed of 60 capsid protein monomers. The method disclosed herein results in each monomer being modified.

[0045] Figure 2: Maps of the RC2 (A), RC6 (B), and RC9 (C) plasmids required for packaging wild-type AAV2, AAV6, and AAV9.

[0046] Figure 3: Comparison of the infection efficiency of AAV2 and its modified AAV in HEK293 cells in vitro.

[0047] The leftmost column shows DAPI-stained nuclei of HEK293 cells. The middle column shows images of red fluorescent protein (RFP) from the same field of view. The rightmost column shows an overlay of the two corresponding images on the left. Higher red fluorescence intensity indicates better AAV expression efficiency.

[0048] Figure 4: Comparison of the infection efficiency of AAV6 and its modified AAV in HEK293 cells in vitro.

[0049] The leftmost column shows DAPI-stained nuclei of HEK293 cells. The middle column shows images of red fluorescent protein (RFP) from the same field of view. The rightmost column shows an overlay of the two corresponding images on the left. Higher red fluorescence intensity indicates better AAV expression efficiency.

[0050] Figure 5: Comparison of the infection efficiency of AAV9 and its modified AAV in HEK293 cells in vitro.

[0051] The leftmost column shows DAPI-stained nuclei of HEK293 cells. The middle column shows images of red fluorescent protein (RFP) from the same field of view. The rightmost column shows an overlay of the two corresponding images on the left. Higher red fluorescence intensity indicates better AAV expression efficiency.

[0052] Figure 6: Quantitative analysis of AAV infection efficiency in HEK293 cells in vitro.

[0053] AAV infection efficiency is defined as the percentage of RFP-positive cells among all DAPI-positive HEK293 cells. Representative images are shown in Figures 3-5. AAV2.1, AAV6.1, and AAV9.1 represent wild-type AAV2, AAV6, and AAV9, respectively. AAV2.2 and AAV2.3 represent engineered AAV2s. AAV6.2 and AAV6.3 represent engineered AAV6s. AAV9.2 and AAV9.3 represent engineered AAV9s.

[0054] Figure 7: Comparison of the infection efficiency of AAV2 and its modified AAV in U251 human glioma cells in vitro.

[0055] The leftmost column shows nuclei of U251 cells stained with DAPI. The middle column shows images of red fluorescent protein (RFP) from the same field of view. The rightmost column shows an overlay of the two corresponding images on the left. Higher red fluorescence intensity indicates better AAV expression efficiency.

[0056] Figure 8: Comparison of the infection efficiency of AAV6 and its modified AAV in U251 human glioma cells in vitro.

[0057] The leftmost column shows nuclei of U251 cells stained with DAPI. The middle column shows images of red fluorescent protein (RFP) from the same field of view. The rightmost column shows an overlay of the two corresponding images on the left. Higher red fluorescence intensity indicates better AAV expression efficiency.

[0058] Figure 9: Comparison of the infection efficiency of AAV9 and its modified AAV in U251 human glioma cells in vitro.

[0059] The leftmost column shows nuclei of U251 cells stained with DAPI. The middle column shows images of red fluorescent protein (RFP) from the same field of view. The rightmost column shows an overlay of the two corresponding images on the left. Higher red fluorescence intensity indicates better AAV expression efficiency.

[0060] Figure 10: Quantitative analysis of AAV infection efficiency in U251 human glioma cells in vitro.

[0061] AAV infection efficiency is defined as the percentage of RFP-positive cells among all DAPI-positive U251 cells. Representative images are shown in Figures 7-9. AAV2.1, AAV6.1, and AAV9.1 represent wild-type AAV2, AAV6, and AAV9, respectively. AAV2.2 and AAV2.3 are engineered AAV2s. AAV6.2 and AAV6.3 are engineered AAV6s. AAV9.2 and AAV9.3 are engineered AAV9s.

[0062] Figure 11: AAV-mediated expression distribution of red fluorescent protein near the lateral ventricle of mice.

[0063] 5 μl of AAV-CAG-RFP virus was slowly injected into the unilateral lateral ventricle of adult mice by a microinjector (3 mice for each AAV, 8.3×10 per mouse). 9 vg). Four weeks after targeted injection, brain tissue was sectioned and scanned with red fluorescence. "V" in the figure marks the location of the lateral ventricle. AAV2.1, AAV6.1, and AAV9.1 are wild-type AAV2, AAV6, and AAV9, respectively. AAV2.2 and AAV2.3 are modified AAV2s. AAV6.2 and AAV6.3 are modified AAV6s. AAV9.2 and AAV9.3 are modified AAV9s.

[0064] Figure 12: Quantification of AAV-mediated red fluorescent protein intensity near the lateral ventricle (A) and hippocampus (B) of mice.

[0065] Relative fluorescence intensity was measured using ImageJ software. No fluorescent protein signal was detected in other brain regions except near the lateral ventricles. AAV2.1, AAV6.1, and AAV9.1 are wild-type AAV2, AAV6, and AAV9, respectively. AAV2.2 and AAV2.3 are modified AAV2s. AAV6.2 and AAV6.3 are modified AAV6s. AAV9.2 and AAV9.3 are modified AAV9s.

[0066] Figure 13: AAV-mediated expression distribution of red fluorescent protein in mouse liver.

[0067] 5 μl of AAV-CAG-RFP virus was slowly injected into the unilateral lateral ventricle of adult mice by a microinjector (3 mice for each AAV, 8.3×10 per mouse). 9 vg). Four weeks after targeted injection, liver tissue was sectioned and scanned for red fluorescence. Stronger red fluorescence signals indicate greater expression of "leaky" AAV. AAV2.1, AAV6.1, and AAV9.1 are wild-type AAV2, AAV6, and AAV9, respectively.

[0068] Figure 14: AAV expression intensity in mouse liver.

[0069] AAV expression intensity is defined as the percentage of RFP-positive hepatocytes among all DAPI-positive hepatocytes. AAV2.1, AAV6.1, and AAV9.1 are wild-type AAV2, AAV6, and AAV9, respectively. AAV2.2 and AAV2.3 are engineered AAV2s. AAV6.2 and AAV6.3 are engineered AAV6s. AAV9.2 and AAV9.3 are engineered AAV9s.

[0070] Figure 15: Detection and quantification of AAV DNA “leaked” into mouse peripheral tissues; A: liver; B: skeletal muscle; C: heart; D: kidney; E: spleen.

[0071] Figure 16: Quantification of AAV RNA leakage into mouse peripheral tissues; A: liver; B: skeletal muscle; C: heart; D: kidney; E: spleen; F: dorsal ganglion.

[0072] Figure 17: qPCR detection of EGFP mRNA levels 72 hours after AAV infection of HEK293 cells, including NC group (average value = 1), AAV6 group (average value = 311.7), AAV6.2 group (average value = 11390), AAV9 group (average value = 84.57) and AAV9.2 group (average value = 545.2).

[0073] Figure 18A and Figure 18B: WB detection of EGFP protein levels 72 hours after AAV infection of HEK293 cells, including AAV6 group (average value = 1), AAV6.2 group (average value = 3.3), AAV9 group (average value = 0.4), and AAV9.2 group (average value = 1.1).

[0074] Figure 19: qPCR detection of EGFP mRNA levels 72 hours after AAV infection of BT474 cells, including NC group (average value = 1), AAV6 group (average value = 50.02), AAV6.2 group (average value = 219.4), AAV9 group (average value = 1.423), and AAV9.2 group (average value = 2.878).

[0075] Figure 20A and Figure 20B: WB detection of EGFP protein levels 72 hours after AAV infection of BT474 cells, including AAV6 group (average value = 1), AAV6.2 group (average value = 2.8), AAV9 group (average value = 0.06), and AAV9.2 group (average value = 0.05).

[0076] Figures 21A to 21I: Schematic diagrams of the results of AAV6 and AAV6.2 infecting cell lines of different origins, respectively, and detecting EGFP fluorescence intensity using a microplate reader. Figure 21A shows NCI-H196 (human small cell lung cancer cells); Figure 21B shows SK-N-SH (human neuroblastoma cells); Figure 21C shows T98G (human glioma cells); Figure 21D shows A172 (human glioblastoma cells); Figure 21E shows U-87MG (human astrocytoblastoma cells); Figure 21F shows SK-BR-3 (human breast cancer cells); Figure 21G shows PC-3 (human prostate cancer cells); Figure 21H shows A-375 (human malignant melanoma cells); and Figure 21I shows HCT116 (human colon cancer cells). DETAILED DESCRIPTION

[0077] In order to make the present disclosure more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise explicitly defined herein, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present disclosure belongs.

[0078] In this specification, the numerical range expressed using "a numerical value A to a numerical value B" means a range including the endpoints A and B.

[0079] In this specification, the use of “substantially” or “essentially” means that the standard deviation from a theoretical model or theoretical data is within a range of 5%, preferably 3%, and more preferably 1%.

[0080] In this specification, the use of "may" includes both the meaning of performing a certain process and the meaning of not performing a certain process.

[0081] As used herein, "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event occurs and instances where it does not.

[0082] In this specification, references to "some specific / preferred embodiments," "other specific / preferred embodiments," "embodiments," etc., mean that the specific elements (e.g., features, structures, properties, and / or characteristics) described in connection with the embodiments are included in at least one embodiment described herein, and may or may not be present in other embodiments. In addition, it should be understood that the elements may be combined in various embodiments in any suitable manner.

[0083] According to the present disclosure, the terms "polypeptide", "protein" and "peptide" are used interchangeably herein to refer to a polymeric form of amino acids of any length, which may include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having similar peptide backbones.

[0084] According to the present disclosure, the terms "nucleic acid molecule," "polynucleotide," "polynucleic acid," and "nucleic acid" are used interchangeably to refer to a polymeric form of nucleotides of any length, whether deoxyribonucleotides or ribonucleotides, or analogs thereof. A polynucleotide can have any three-dimensional structure and can perform any function, known or unknown. Non-limiting examples of polynucleotides include genes, gene fragments, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, control regions, isolated RNA of any sequence, nucleic acid probes, and primers. Nucleic acid molecules can be linear or circular.

[0085] In accordance with the present disclosure, the three letter and one letter codes for amino acids are as described in J. biol. chem, 243, p3558 (1968).

[0086] According to the present disclosure, amino acid "addition" refers to the addition of amino acids at the C-terminus or N-terminus of an amino acid sequence. According to the present disclosure, amino acid "deletion" refers to the deletion of 1, 2 or more amino acids from an amino acid sequence. According to the present disclosure, amino acid "insertion" refers to the insertion of amino acid residues at appropriate positions in an amino acid sequence. The inserted amino acid residues may also be all or partially adjacent to each other, or the inserted amino acids may not be adjacent to each other. According to the present disclosure, amino acid "substitution" refers to the replacement of an amino acid residue at a certain position in an amino acid sequence by other amino acid residues; wherein, the "substitution" may be a conservative amino acid substitution.

[0087] According to the present disclosure, "conservative modification", "conservative substitution" or "conservative replacement" refers to the replacement of an amino acid in a protein with other amino acids having similar characteristics (e.g., charge, side chain size, hydrophobicity / hydrophilicity, main chain conformation and rigidity, etc.), so that changes can be made frequently without changing the biological activity of the protein. It is known to those skilled in the art that, in general, single amino acid replacements in non-essential regions of a polypeptide do not substantially change the biological activity (see, e.g., Watson et al. (1987) Molecular Biology of the Gene, The Benjamin / Cummings Pub. Co., p. 224, (4th edition)). In addition, replacements of amino acids with similar structure or function are unlikely to destroy biological activity. Exemplary conservative replacements are set forth below in "Exemplary Amino Acid Conservative Replacements".

[0088] Exemplary conservative amino acid substitutions

[0089] According to the present disclosure, "moderate to very high stringency conditions" include "moderate stringency conditions," "moderate-high stringency conditions," "high stringency conditions," or "very high stringency conditions," which describe conditions for nucleic acid hybridization and washing. Guidance for conducting hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6, which is incorporated herein by reference. Aqueous and non-aqueous methods are described in this document, and either method can be used. For example, specific hybridization conditions are as follows: (1) low stringency hybridization conditions are in 6× sodium chloride / sodium citrate (SSC) at about 45°C, followed by two washes in 0.2×SSC, 0.1% SDS at at least 50°C (the wash temperature can be increased to 55°C for low stringency conditions); (2) moderate stringency hybridization conditions are in 6×SSC at about 45°C, followed by one or more washes in 0.2×SSC, 0.1% SDS at 60°C; (3) high stringency hybridization conditions are in 6×SSC at about 45°C, followed by one or more washes in 0.2×SSC, 0.1% SDS at 65°C, and preferably; (4) very high stringency hybridization conditions are 0.5 M sodium phosphate, 7% SDS at 65°C, followed by one or more washes in 0.2×SSC, 1% SDS at 65°C.

[0090] "Identity" refers to the sequence similarity between two polynucleotide sequences or between two polypeptides. When a position in the two compared sequences is occupied by the same base or amino acid monomer subunit, for example, if every position in two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percent identity between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared × 100%. For example, if 6 out of 10 positions in the two sequences match or are homologous when the sequences are optimally aligned, then the two sequences are 60% homologous. Generally, a comparison is made when the two sequences are aligned to achieve the maximum percent identity.

[0091] "Administer," "give," and "treat" as applied to an animal, a human, a laboratory subject, a cell, a tissue, an organ, or a biological fluid, refers to the contact of an exogenous drug, therapeutic agent, diagnostic agent, or composition with an animal, a human, a subject, a cell, a tissue, an organ, or a biological fluid. "Administer," "give," and "treat" can refer to, for example, therapeutic, pharmacokinetics, diagnostics, research, and experimental procedures. Treatment of cells includes contact of an agent with a cell, and contact of an agent with a fluid, wherein the fluid is in contact with the cell. "Administer," "give," and "treat" also mean the in vitro and ex vivo treatment of, for example, a cell, by an agent, a diagnostic agent, a binding composition, or by another cell. "Treatment," as applied to a human, veterinary, or research subject, refers to therapeutic, prophylactic or preventative measures, research, and diagnostic applications.

[0092] "Treatment" means administering an internal or external therapeutic agent, such as any of the antibodies disclosed herein, to a patient who has one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect. Typically, the therapeutic agent is administered in an amount effective to alleviate one or more symptoms of the disease in the patient or population being treated, either by inducing regression of such symptoms or inhibiting the progression of such symptoms to any clinically measurable degree. The amount of therapeutic agent effective to alleviate any specific disease symptom (also referred to as a "therapeutically effective amount") can vary according to a variety of factors, such as the patient's disease state, age, and weight, and the ability of the drug to produce the desired therapeutic effect in the patient. Whether the symptoms of the disease have been alleviated can be assessed by any clinical test commonly used by physicians or other health care professionals to assess the severity or progression of such symptoms.

[0093] As used herein, the term "prevention" refers to the prophylactic treatment of a subject who does not currently have a disease or has not had a disease in the past but is at risk of developing a disease, or who has had a disease in the past and does not currently have a disease but is at risk of recurrence of the disease. In certain embodiments, the subject is at increased risk of developing a disease or at increased risk of recurrence of a disease compared to the average healthy member of a population of subjects.

[0094] An "effective amount" encompasses an amount sufficient to ameliorate or prevent the symptoms or conditions of a medical condition. An effective amount also means an amount sufficient to permit or facilitate diagnosis. The effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition to be treated, the patient's overall health, the route and dosage of administration, and the severity of side effects. An effective amount can be the maximum dose or dosage regimen that avoids significant side effects or toxic effects.

[0095] As used herein, a "therapeutically effective amount" is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or sufficient to delay or minimize one or more symptoms associated with the condition. A therapeutically effective amount refers to an amount of a therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment of a condition. The term "therapeutically effective amount" can include an amount that improves overall therapy; reduces or avoids symptoms, signs, or causes of a condition; and / or enhances the therapeutic efficacy of another therapeutic agent.

[0096] As used herein, a "prophylactically effective amount" is an amount sufficient to prevent a condition or one or more symptoms associated with a condition or to prevent its recurrence. A prophylactically effective amount refers to an amount of a therapeutic agent, alone or in combination with other agents, that provides a prophylactic benefit in preventing a condition. The term "prophylactically effective amount" may include an amount that improves overall prevention or enhances the prophylactic efficacy of another prophylactic agent.

[0097] In this specification, the term "subject" refers to a human (i.e., a male or female of any age, for example, a pediatric subject (e.g., an infant, child, or adolescent) or an adult subject (e.g., a young, middle-aged, or elderly person)) or a non-human animal. In certain embodiments, the non-human animal is a mammal (e.g., a primate (e.g., a cynomolgus monkey or a rhesus monkey), a commercially relevant mammal (e.g., a cow, pig, horse, sheep, goat, cat, or dog), or a bird. The non-human animal can be male or female at any stage of development. The non-human animal can be a transgenic animal or a genetically engineered animal.

[0098] Detailed Description of the Invention

[0099] The present invention selected the RGD short peptide GRGDSP (SEQ ID NO: 23) derived from human fibronectin as a targeting peptide, and inserted it into the capsid protein of AAV2, AAV6, and AAV9 using genetic engineering technology, and evaluated its manufacturability, in vivo and in vitro cell infection efficiency, and targeting to brain tissue.

[0100] AAV capsid protein

[0101] In some embodiments of the present disclosure, an AAV capsid protein is provided, which includes a targeting peptide comprising one or more of the following sequences:

[0102] (i) the amino acid sequence set forth in SEQ ID NO: 23;

[0103] (ii) an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 23, and that has or partially has the function of the amino acid sequence of SEQ ID NO: 23;

[0104] (iii) an amino acid sequence in which one or more amino acid residues are added, substituted, deleted or inserted into the amino acid sequence of SEQ ID NO: 23, and which has or partially has the function of the amino acid sequence of SEQ ID NO: 23; or

[0105] (iv) an amino acid sequence encoded by a nucleotide sequence that hybridizes with a polynucleotide sequence encoding the amino acid sequence as shown in SEQ ID NO: 23 under stringent conditions, and the amino acid sequence has or partially has the function of the amino acid sequence as shown in SEQ ID NO: 23, wherein the stringent conditions are moderate stringency conditions, medium-high stringency conditions, high stringency conditions or very high stringency conditions.

[0106] In the present disclosure, AAV is a tiny, non-enveloped virus with a 25 nm capsid. No disease is known or has been shown to be associated with the wild-type virus. AAV has a single-stranded DNA (ssDNA) genome. AAV has been shown to exhibit long-term episomal transgene expression. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. The space limit for exogenous DNA is approximately 4.7 kb. AAV vectors, such as the AAV vectors described in Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985), can be used to introduce DNA into cells. AAV vectors have been used to introduce a variety of nucleic acids into different cell types (see, e.g., Hermonat et al., Proc. Natl. Acad. Sci. USA 81:6466-6470 (1984); Tratschin et al., Mol. Cell. Biol. 4:2072-2081 (1985); Wondisford et al., Mol. Endocrinol. 2:32-39 (1988); Tratschin et al., J. Virol. 51:611-619 (1984); and Flotte et al., J. Biol. Chem. 268:3781-3790 (1993). There are many AAV variants to choose from (over 100 have been cloned), and AAV variants have been identified based on desired properties.

[0107] In some embodiments, the AAV is selected from one or more of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, rh.10, rh.39, rh.43, and rh.74.

[0108] In some preferred embodiments, the AAV is selected from one or more of AAV2, AAV6, and AAV9.

[0109] The AAV capsid is an icosahedron, composed of 60 VP capsid protein monomers, including 5 VP1 monomers, 5 VP2 monomers and 50 VP3 monomers. VP1, VP2, and VP3 monomers are all transcribed and translated from the Cap gene of AAV. VP1 is the longest, containing about 735 amino acids. VP2 and VP3 are "short sections" of VP1, which do not contain the amino acids at the N-terminus of the VP1 protein. By convention, the capsid protein modification sites are named according to the amino acid sequence of the VP1 protein. For example, the 453 insertion site of AAV2 refers to the insertion of a short peptide after the 453rd amino acid of the VP1 monomer of AAV2 (containing 735 amino acids), so that AAV2 VP1, VP2, and VP3 all contain this short peptide; the 454 insertion site of AAV6 refers to the insertion of a short peptide after the 454th amino acid of the VP1 monomer of AAV6 (containing 736 amino acids), so that AAV6 VP1, VP2, and VP3 all contain this short peptide.

[0110] In some embodiments, AAV2 comprises AAV2 VP1, AAV2 VP2, and / or AAV2 VP3. In some embodiments, AAV6 comprises AAV6 VP1, AAV6 VP2, and / or AAV6 VP3. In some embodiments, AAV9 comprises AAV9 VP1, AAV9 VP2, and / or AAV9 VP3.

[0111] In this specification, the insertion sites of the targeting peptides in VP2 and VP3 are described according to their corresponding amino acid positions in VP1. For example, the amino acid sequence of AAV2 VP2 (SEQ ID NO: 15) has a total of 598 amino acids, corresponding to amino acids 138-735 of AAV2 VP1.

[0112] Exemplarily, the amino acid sequence of AAV2 VP1 is shown below (SEQ ID NO: 14):

[0113] (735 amino acids in total)

[0114] The amino acid sequence of AAV2 VP2 is shown below (SEQ ID NO: 15):

[0115] (AAV2 VP1 amino acids 138-735, 598 amino acids total)

[0116] The amino acid sequence of AAV2 VP3 is shown below (SEQ ID NO: 16):

[0117] (AAV2 VP1 amino acids 203-735, 533 amino acids total)

[0118] The amino acid sequence of AAV6 VP1 is shown below (SEQ ID NO: 17):

[0119] (736 amino acids in total)

[0120] The amino acid sequence of AAV6 VP2 is shown below (SEQ ID NO: 18):

[0121] (AAV6 VP1 amino acids 138-736, 599 amino acids total)

[0122] The amino acid sequence of AAV6 VP3 is shown below (SEQ ID NO: 19): MASGGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSASTGASNDNHYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTTNDGV TTIANNLTSTVQVFSDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLNRTQNQSGSAQNKDLLFSR GSPAGMSVQPKNWLPGPCYRQQRVSKTKTDNNNSNFTWTGASKYNLNGRESIINPGTAMASHKDDKDKFFPMSGVMIFGKESAGASNTALDNVMITDEEEIKATNPVATERFGTVAVNLQSSSTDPATGDVHVMG ALPGMVWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPAEFSATKFASFITQYSTGQVSVEIEWELQKENSKRWNPEVQYTSNYAKSANVDFTVDNNGLYTEPRPIGTRYLTRPL

[0123] (AAV6 VP1 amino acids 203-736, a total of 534 amino acids)

[0124] The amino acid sequence of AAV9 VP1 is shown below (SEQ ID NO: 20):

[0125] (736 amino acids in total)

[0126] The amino acid sequence of AAV9 VP2 is shown below (SEQ ID NO: 21):

[0127] (AAV9 VP1 amino acids 138-736, 599 amino acids total)

[0128] The amino acid sequence of AAV9 VP3 is shown below (SEQ ID NO: 22):

[0129] (AAV9 VP1 amino acids 203-736, a total of 534 amino acids)

[0130] In some embodiments, the targeting peptide is inserted at position 453 of amino acid and / or position 588 of amino acid of AAV2 VP1, AAV2 VP2 and / or AAV2 VP3. Specifically, the targeting peptide is inserted at position 453 of amino acid and / or position 588 of amino acid of AAV2 VP1, so that the targeting peptide is inserted at position 453 of amino acid and / or position 588 of amino acid of AAV2 VP2 corresponding to position 453 of amino acid and / or position 588 of amino acid of AAV2 VP1, and at position 453 of amino acid and / or position 588 of amino acid of AAV2 VP3 corresponding to position 453 of amino acid and / or position 588 of amino acid of AAV2 VP1.

[0131] In some embodiments, the targeting peptide is inserted at the position of amino acid 454 and / or amino acid 588 of AAV6 VP1, AAV6 VP2, and / or AAV6 VP3. Specifically, the targeting peptide is inserted at the position of amino acid 454 or amino acid 588 of AAV6 VP1, so that the position of amino acid 454 and / or amino acid 588 corresponding to AAV6 VP1 in AAV6 VP2, and the position of amino acid 454 and / or amino acid 588 corresponding to AAV6 VP1 in AAV6 VP3 are both inserted with the targeting peptide.

[0132] In some embodiments, the targeting peptide is inserted at the position of amino acid 455 and / or amino acid 588 of AAV9 VP1, AAV9 VP2, and / or AAV9 VP3. Specifically, the targeting peptide is inserted at the position of amino acid 455 or amino acid 588 of AAV9 VP1, so that the position of amino acid 455 and / or amino acid 588 corresponding to AAV9 VP1 in AAV9 VP2, and the position of amino acid 455 and / or amino acid 588 corresponding to AAV9 VP1 in AAV9 VP3 are both inserted with the targeting peptide.

[0133] In some preferred embodiments, the targeting peptide is inserted at amino acid 453 of AAV2 VP1, such that the position corresponding to amino acid 453 of AAV2 VP1 in AAV2 VP2 and the position corresponding to amino acid 453 of AAV2 VP1 in AAV2 VP3 are both inserted with the targeting peptide. In some preferred embodiments, the targeting peptide is inserted at amino acid 454 of AAV6 VP1, such that the position corresponding to amino acid 454 of AAV6 VP1 in AAV6 VP2 and the position corresponding to amino acid 454 of AAV6 VP1 in AAV6 VP3 are both inserted with the targeting peptide. In some preferred embodiments, the targeting peptide is inserted at amino acid 588 of AAV9 VP1, such that the position corresponding to amino acid 588 of AAV9 VP1 in AAV9 VP2 and the position corresponding to amino acid 588 of AAV9 VP1 in AAV9 VP3 are both inserted with the targeting peptide.

[0134] The targeting peptides disclosed herein can be modified according to methods known in the art for generating peptidomimetics. See, e.g., Qvit et al., Drug Discov Today. 2017 Feb;22(2):454-462; Farhadi and Hashemian, Drug Des Devel Ther. 2018;12:1239-1254; Avan et al., Chem. Soc. Rev., 2014, 43,3575-3594; Pathak et al., Indo American Journal of Pharmaceutical Research, 2015.8; Kazmierski, WM, ed., Peptidomimetics Protocols, Human Press (Totowa NJ 1998); Goodman et al., eds., Houben-Weyl Methods of Organic Chemistry: Synthesis of Peptides and Peptidomimetics, Thiele Verlag (New York 2003); and Mayo et al., J. Biol. Chem., 278:45746 (2003). In some cases, these modified peptidomimetic forms of the peptides and fragments disclosed herein exhibit enhanced in vivo stability relative to non-peptidomimetic peptides.

[0135] The method of producing a peptidomimetic comprises replacing one or more, for example all, amino acids in a peptide sequence with a D-amino acid enantiomer. Such a sequence is referred to herein as a "retro" sequence. In another method, the order of the amino acid residues from the N-terminus to the C-terminus is reversed so that the order of the amino acid residues from the N-terminus to the C-terminus of the original peptide becomes the order of the amino acid residues from the C-terminus to the N-terminus in the modified peptidomimetic. Such a sequence can be referred to as an "inverso" sequence.

[0136] The peptidomimetics can be in reverse and inverted form, i.e., "retro-inverso" forms of the peptides disclosed herein. The new peptidomimetics can be composed of D-amino acids arranged so that the order of amino acid residues from the N-terminus to the C-terminus in the peptidomimetic corresponds to the order of amino acid residues from the C-terminus to the N-terminus in the original peptide.

[0137] Other methods for preparing peptidomimetics include replacing one or more amino acid residues in a peptide with chemically different but recognized functional analogs of amino acids, i.e., artificial amino acid analogs. Artificial amino acid analogs include β-amino acids, β-substituted β-amino acids ("β 3 -amino acids”), phosphorus-containing analogs of amino acids such as -aminophosphonic acid and -aminophosphinic acid, and amino acids with non-peptide bonds. Artificial amino acids can be used to generate peptidomimetics, such as peptoid oligomers (e.g., peptoid amide or ester analogs), β-peptides, cyclic peptides, oligoureas or oligocarbamate peptides; or heterocyclic molecules.

[0138] polynucleotides

[0139] In some embodiments of the present disclosure, a polynucleotide encoding the AAV capsid protein of the present disclosure is provided.

[0140] The polynucleotides disclosed herein may be in the form of DNA or RNA. DNA forms include cDNA, genomic DNA, or synthetic DNA. DNA may be single-stranded or double-stranded. DNA may be a coding strand or a non-coding strand.

[0141] The AAV capsid protein encoding the present invention includes: a coding sequence encoding only the AAV capsid protein / targeting peptide; a coding sequence of the AAV capsid protein / targeting peptide and various additional coding sequences; a coding sequence of the AAV capsid protein / targeting peptide (and optional additional coding sequences) and non-coding sequences.

[0142] The "polynucleotide encoding an AAV capsid protein / targeting peptide" may include a polynucleotide encoding the AAV capsid protein / targeting peptide, or may include additional coding and / or non-coding sequences.

[0143] The present disclosure also relates to polynucleotides that hybridize to the aforementioned sequences and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present disclosure particularly relates to polynucleotides that hybridize to the polynucleotides described herein under stringent conditions, such as moderate stringency, medium-high stringency, high stringency, or very high stringency.

[0144] AAV and AAV vectors

[0145] In some embodiments of the present disclosure, an AAV is provided, comprising the AAV capsid protein described in the present disclosure.

[0146] In some embodiments, the AAV further comprises a transgene.

[0147] In some specific embodiments, the transgene comprises a nucleotide sequence encoding a gene product. A "gene" is a polynucleotide comprising at least one open reading frame that, upon transcription and translation, encodes a specific protein. A "gene product" is a molecule produced by expression of a specific gene. Gene products include, for example, polypeptides, aptamers, interfering RNA, mRNA, and the like.

[0148] In some specific embodiments, the transgene is a therapeutic transgene, a preventive transgene, or a diagnostic transgene.

[0149] In some exemplary embodiments, the transgene is a therapeutic transgene that encodes a gene sequence of a therapeutic agent, such as a gene sequence encoding an anti-cancer (brain tumor) agent, or a gene sequence encoding a therapeutic agent for other brain diseases.

[0150] Some aspects of the present disclosure also provide a transgene delivery vector comprising the AAV described in the present disclosure.

[0151] Pharmaceutical compositions and methods of administration

[0152] In some embodiments of the present disclosure, a pharmaceutical composition is provided, comprising:

[0153] (a) the AAV described above, or the transgene delivery vector described above; and, optionally,

[0154] (b) a pharmaceutically acceptable carrier.

[0155] In some embodiments, the pharmaceutical composition described in the present disclosure contains the above-mentioned AAV or the above-mentioned transgene delivery vector as an active ingredient, wherein the AAV or transgene delivery vector comprises (i) a targeting peptide and (ii) a transgene, such as a therapeutic transgene, illustratively, a therapeutic agent for treating brain tumors or other brain diseases.

[0156] As used herein, the term "pharmaceutically acceptable carrier" includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.

[0157] Pharmaceutical compositions are typically formulated to be compatible with their intended route of administration. Examples of routes of administration include parenteral, such as intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular, intracerebrospinal fluid, intracerebral tissue, or intratumoral injection or infusion. Thus, delivery can be systemic or local.

[0158] Methods for preparing suitable pharmaceutical compositions are known in the art, see, for example, Remington: The Science and Practice of Pharmacy, 21st ed., 2005; and Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs (Dekker, NY). For example, solutions or suspensions for parenteral use may include the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerol, propylene glycol, or other synthetic solvents; an antibacterial agent, such as benzyl alcohol or methyl paraben; an antioxidant, such as ascorbic acid or sodium bisulfite; a chelating agent, such as ethylenediaminetetraacetic acid; a buffer, such as acetate, citrate or phosphate, and an agent for adjusting tonicity, such as sodium chloride or glucose. The pH can be adjusted with an acid or base, such as hydrochloric acid or sodium hydroxide. Parenteral formulations can be packaged in ampoules, disposable syringes, or multiple-dose vials made of glass or plastic.

[0159] The pharmaceutical composition suitable for injectable use may include sterile aqueous solution (water soluble) or dispersion, and sterile powder for the temporary preparation of sterile injectable solution or dispersion. For intravenous administration, suitable carriers include physiological saline, antibacterial water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should flow to a degree that is easy to inject. It should be stable under manufacturing and storage conditions, and must prevent the contamination of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium, which contains, for example, water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol, etc.) and their appropriate mixture. For example, suitable fluidity can be maintained by using coatings such as lecithin, by maintaining the required particle size and by using a surfactant in the case of dispersion. The effect of preventing microorganisms can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0160] Sterile injectable solutions can be prepared by incorporating the desired amount of the active compound into an appropriate solvent with one or a combination of the ingredients listed above, followed by filtration sterilization. Typically, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other ingredients desired from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, preferred methods of preparation are vacuum drying and freeze drying, which produce a powder of the active ingredient and any other desired ingredients from a previously sterile-filtered solution.

[0161] In one embodiment, the therapeutic compound is prepared together with a carrier that protects the therapeutic compound from rapid elimination from the body, such as as a controlled release formulation, including implants and microencapsulated drug delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Such preparations can be prepared using standard techniques, or commercially available from Alza Corporation and Nova Pharmaceuticals, Inc., etc. Liposomal suspensions (including liposomes targeted to selected cells with monoclonal antibodies to cellular antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent number 4,522,811.

[0162] The pharmaceutical compositions can be included in a kit, container, pack, or dispenser together with instructions for administration.

[0163] Uses and methods

[0164] In some embodiments of the present disclosure, use of the adeno-associated virus described herein, the transgene delivery vector described herein, and / or the pharmaceutical composition described herein in preparing an agent for delivering a transgene to a cell is provided.

[0165] In other embodiments of the present disclosure, a method for delivering a transgene to a cell is provided, comprising the step of contacting the cell with the AAV of the present disclosure, the transgene delivery vector of the present disclosure, and / or the pharmaceutical composition of the present disclosure.

[0166] The AAVs described herein can be used to deliver transgenes, such as therapeutic transgenes, to tissues, such as the central nervous system (brain), heart, muscle, or dorsal root ganglia or spinal cord (peripheral nervous system). In some embodiments, the AAVs described herein can deliver transgenes, such as therapeutic transgenes, to specific brain regions, such as the cortex, cerebellum, hippocampus, substantia nigra, or amygdala. In some embodiments, the AAVs described herein can deliver transgenes / therapeutic transgenes to neurons, astrocytes, and / or glial cells.

[0167] In some embodiments, the AAV described in the present disclosure is used to deliver a nucleic acid sequence encoding a therapeutic agent to a subject with a brain disease. In some specific embodiments, the AAV described in the present disclosure is used to deliver a nucleic acid sequence encoding a therapeutic agent to a subject with a brain tumor. Brain tumors include gliomas (e.g., glioblastoma multiforme (GBM)), metastatic cancers (e.g., from lung cancer, breast cancer, melanoma, or colon cancer), meningiomas, pituitary adenomas, and acoustic neuromas. Therefore, an AAV containing a targeting peptide as described herein and encoding an immunotherapeutic agent can be systemically administered, for example, intravenously, to a subject diagnosed with a brain tumor.

[0168] In other specific embodiments, the AAV described in the present disclosure is used to deliver nucleic acid sequences encoding therapeutic agents to subjects suffering from other brain diseases, such as subjects suffering from cerebrovascular diseases (exemplarily, cerebral arteriosclerosis, cerebral vascular stenosis, cerebral infarction, cerebral hemorrhage, arteriovenous malformation, aneurysm, etc.); brain infectious diseases (exemplarily, encephalitis, meningitis); neurodegenerative diseases (exemplarily, Alzheimer's disease, Parkinson's disease), but are not limited thereto.

[0169] In some embodiments, the AAV described in the present disclosure can also be co-administered with a chemotherapeutic agent. In some embodiments, the chemotherapeutic agent is a toxin or cytotoxic drug, including but not limited to temozolomide, lomustine, or a combination thereof. See, for example, Herrlinger et al., Lancet. February 16, 2019; 393(10172): 678-688. The method may also include administering radiation, surgical resection, or both.

[0170] In some specific embodiments of the present disclosure, provided is the use of the adeno-associated virus described in the present disclosure, the transgene delivery vector described in the present disclosure, and / or the pharmaceutical composition described in the present disclosure in the preparation of a drug for treating a disease.

[0171] In other specific embodiments of the present disclosure, a method for treating a disease is provided, comprising the step of administering the adeno-associated virus described in the present disclosure, the transgene delivery vector described in the present disclosure, and / or the pharmaceutical composition described in the present disclosure to a subject.

[0172] In the present disclosure, the disease can be any disease that can be treated by an adeno-associated virus carrying a transgene. In some preferred embodiments, the disease can be a brain disease. In some specific embodiments, the brain disease includes brain tumors; cerebrovascular diseases (exemplarily, cerebral arteriosclerosis, cerebral vascular stenosis, cerebral infarction, cerebral hemorrhage, arteriovenous malformation, aneurysm, etc.); brain infectious diseases (exemplarily, encephalitis, meningitis); neurodegenerative diseases (exemplarily, Alzheimer's disease, Parkinson's disease), but are not limited thereto.

[0173] Example

[0174] The present disclosure is further described in detail below in conjunction with specific embodiments. The examples provided are only for the purpose of illustrating the present disclosure and are not intended to limit the scope of the present disclosure. The examples provided below can serve as a guide for further improvements by those of ordinary skill in the art and do not constitute a limitation of the present disclosure in any way.

[0175] Unless otherwise specified, the experimental methods in the following examples are conventional methods and were performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials and reagents used in the following examples, unless otherwise specified, were all commercially available.

[0176] Materials and methods

[0177] The following examples utilize a conventional three-plasmid co-transfection method to prepare recombinant AAV. The three plasmids include an RC plasmid (containing the nucleotide sequence of the capsid Cap), a Helper plasmid (providing auxiliary factors required for the generation of AAV), and a pAAV plasmid (providing the nucleotide sequence to be delivered, often containing a promoter and cDNA required for protein translation, etc.). The serotype of AAV depends on the RC plasmid. For example, RC2 is used to package and prepare AAV2 type, RC6 is used to package and prepare AAV6 type, and RC9 is used to package and prepare AAV9 type. The modification of the capsid is achieved by genetically modifying the RC plasmid.

[0178] 1. Construction of AAV capsid plasmid

[0179] The following examples used three capsid plasmids: RC2, RC6, and RC9 (the nucleotide sequence of RC2 is shown in SEQ ID NO: 1, the nucleotide sequence of RC6 is shown in SEQ ID NO: 2, and the nucleotide sequence of RC9 is shown in SEQ ID NO: 3). Using molecular biology techniques, the nucleotide sequence corresponding to the short peptide GRGDSP (SEQ ID NO: 4) was inserted into the VP1 gene (SEQ ID NO: 5) in the RC2 plasmid at amino acid position 453, resulting in the corresponding RC2.2 plasmid (SEQ ID NO: 6). Similarly, the nucleotide sequence corresponding to the short peptide GRGDSP (SEQ ID NO: 4) was inserted into the VP1 gene (SEQ ID NO: 5) in the RC2 plasmid at amino acid position 588, resulting in the corresponding RC2.3 plasmid (SEQ ID NO: 7). The nucleotide sequence corresponding to the short peptide GRGDSP (SEQ ID NO: 4) was inserted into the VP1 gene (SEQ ID NO: 8) in the RC6 plasmid at amino acid position 454, resulting in the corresponding RC6.2 plasmid (SEQ ID NO: 9). The nucleotide sequence corresponding to the short peptide GRGDSP (SEQ ID NO: 4) was inserted into the RC6 plasmid at the amino acid 588 position of the VP1 gene (SEQ ID NO: 8) corresponding to amino acid 455, resulting in the RC9.2 plasmid (SEQ ID NO: 12). The nucleotide sequence corresponding to the short peptide GRGDSP (SEQ ID NO: 4) was inserted into the RC9 plasmid at the amino acid 588 position of the VP1 gene (SEQ ID NO: 11) corresponding to amino acid 455, resulting in the RC9.3 plasmid (SEQ ID NO: 13). All nucleotide synthesis and plasmid construction work was performed by Nanjing GenScript Co., Ltd. The relevant specific sequences are shown below.

[0180] SEQ ID NO: 1 (RC2 plasmid nucleotide sequence):

[0181] SEQ ID NO: 2 (RC6 plasmid nucleotide sequence):

[0182] SEQ ID NO: 3 (RC9 plasmid nucleotide sequence):

[0183] SEQ ID NO: 4 (nucleotide sequence corresponding to the short peptide GRGDSP):

[0184] SEQ ID NO: 5 (AAV2 VP1 gene sequence)

[0185] SEQ ID NO: 6 (RC2.2 plasmid nucleotide sequence):

[0186] SEQ ID NO: 7 (RC2.3 plasmid nucleotide sequence):

[0187] SEQ ID NO: 8 (AAV6 VP1 gene sequence):

[0188] SEQ ID NO: 9 (RC6.2 plasmid nucleotide sequence):

[0189] SEQ ID NO: 10 (RC6.3 plasmid nucleotide sequence):

[0190] SEQ ID NO: 11 (AAV9 VP1 gene sequence):

[0191] SEQ ID NO: 12 (RC9.2 plasmid nucleotide sequence):

[0192] SEQ ID NO: 13 (RC9.3 plasmid nucleotide sequence):

[0193] 2. AAV virus packaging and titer determination

[0194] AAV virus packaging was performed using the commonly used three-plasmid transfection method. The RC plasmid, Helper plasmid, and pAAV-CAG-RFP plasmid were chemically transfected into HEK293 cells. AAV viral particles were isolated and purified from HEK293T cells using an iodixanol concentration gradient. AAV titers were determined using the commonly used qPCR method. All AAVs use the CAG universal promoter and are used to express red fluorescent protein (RFP) targeted to the cell nucleus. AAV virus packaging and titer determination were completed by Guangzhou-based Paigen Genetics. Paigen Genetics provided reagents and equipment other than the RC plasmid.

[0195] 3. In vitro cell AAV infection efficiency detection

[0196] To verify the infection efficiency of various AAVs in cultured cells in vitro, the tested cells (HEK293 cells and U251 human glioma cells) were seeded into 24-well cell culture plates at a density of 100,000 cells per well. 9 vg (viral genome; equivalent to genome copies) of the AAV to be tested, with six replicate wells prepared for each AAV. After 4 days of incubation, cells were fixed with 4% paraformaldehyde for 15 minutes. 0.05% DAPI was then used to stain cell nuclei. Finally, all cells were photographed using a fluorescence microscope for quantitative analysis.

[0197] 4. In vivo mouse intracerebroventricular injection and AAV infection efficiency detection

[0198] All in vivo mouse experiments were performed by Wuhan Sewell. Female C57BL6 mice aged 6-8 weeks were deeply anesthetized and fixed to a positioning frame. After the mouse's lateral ventricle was located (coordinates: bregma as 0, bregma posterior to -0.11 to -0.35 mm, 0.90-0.10 mm lateral to, and needle insertion depth of 2.2 mm), 5 μl of AAV virus was slowly injected into the unilateral lateral ventricle using a microsyringe (8.3 × 10 per mouse). 9 vg).

[0199] After localized injection, the mice were maintained for 4 weeks, then the hearts were perfused with pre-chilled PBS and sampled. Brain tissue and portions of liver tissue were snap-frozen, sliced, and imaged with fluorescence. The remaining liver, skeletal muscle, heart, kidney, spleen, pancreas, and dorsal ganglion (DRG) tissues were snap-frozen, AAV DNA and RNA were extracted, and quantified using qPCR.

[0200] Example 1: Acquisition of modified AAV

[0201] As shown in Figure 1, in this example, by molecular modification of the capsid plasmids RC2, RC6, and RC9 (Figure 2), the short peptide GRGDSP was inserted into the 453 and 588 sites of the wild-type AAV2 (also named AAV2.1), thereby obtaining the modified AAV2.2 and AAV2.3, respectively; the short peptide GRGDSP was inserted into the 454 and 588 sites of the wild-type AAV6 (also named AAV6.1), thereby obtaining the modified AAV6.2 and AAV6.3, respectively; the short peptide GRGDSP was inserted into the 453 and 588 sites of the wild-type AAV9 (also named AAV9.1), thereby obtaining the modified AAV9.2 and AAV9.3, respectively. All 6 modified AAVs can be successfully packaged, and the resulting viral titers are roughly equivalent to those of the wild type (Table 1). This example illustrates that the newly inserted GRGDSP short peptide at the designed site is well compatible with the original AAV capsid.

[0202] Table 1:

[0203] Among them, “-” means that no targeting peptide is inserted.

[0204] Example 2: Enhanced cell infection efficiency of modified AAV

[0205] In order to detect the cell infection efficiency of the modified AAV, this example first used in vitro cultured tool cells HEK293 cells. As shown in Figures 3 to 5, most AAVs can infect HEK293 cells well. Many HEK293 cells with positive DAPI nucleus staining also express AAV-mediated red fluorescence. Compared with wild-type AAV2 (AAV2.1) (Figure 3), the infection efficiency of AAV2.2 is comparable, while the infection efficiency of AAV2.3 is reduced. Compared with wild-type AAV6 (AAV6.1) (Figure 4), the infection efficiency of AAV6.2 and AAV6.3 is enhanced. Compared with wild-type AAV9 (AAV9.1) (Figure 5), the infection efficiency of AAV9.2 and AAV9.3 is also enhanced. The positive percentages of each AAV infection are shown in Figure 6 (significant difference analysis method: ANOVA plus Dunnett post hoc comparison of modified and wild-type AAVs, ****P<0.0001).

[0206] This example also uses in vitro cultured U251 human glioma cells to further evaluate the infection efficiency of all AAVs. As shown in Figures 7 to 9, the infection efficiency of each AAV on U251 tumor cells varies. Compared with wild-type AAV2 (AAV2.1) (Figure 7), the infection efficiency of AAV2.2 is comparable, while the infection efficiency of AAV2.3 is reduced. Compared with wild-type AAV6 (AAV6.1) (Figure 8), the infection efficiency of AAV6.2 is enhanced, with significant differences, while the infection efficiency of AAV6.3 is reduced. Compared with wild-type AAV9 (AAV9.1) (Figure 9), the infection efficiency of AAV9.2 is significantly enhanced, while the infection efficiency of AAV9.3 is slightly reduced, but still within the usable range. In comparison, wild-type AAV2 and AAV6 seem to have a higher affinity for U251 tumor cells than wild-type AAV9. The positive percentages of each AAV infection are shown in FIG10 (Significant difference analysis method: ANOVA plus Dunnett post hoc comparison of modified and wild-type AAVs, ****P<0.0001).

[0207] In summary, inserting the GRGDSP short peptide into the 453 / 454 / 455 sites of AAV2 / 6 / 9 can enhance their cell infection efficiency. Although the infection efficiency of AAV9.3 is slightly reduced, it is still within the acceptable range.

[0208] Example 3: Modified AAV has higher targeting to the brain

[0209] To investigate the brain targeting properties of various AAVs, this example directly injected an AAV carrying the red fluorescent protein gene (AAV-CAG-RFP) into the lateral ventricles of adult mice and observed AAV expression in brain tissue. Previous studies have shown that many AAVs injected into the lateral ventricles can leak into the systemic bloodstream, potentially infecting other tissues and posing a safety risk of off-target effects. A key focus of this example was to investigate whether the modified AAVs would reduce expression in tissues other than the brain. As shown in Figures 11 and 12 , after intracerebroventricular injection, AAV-mediated red fluorescence was primarily expressed in brain tissue near the lateral ventricles. Wild-type AAV2 (AAV2.1) had a low overall expression efficiency, while modified AAV2.2 showed a slight improvement, while AAV2.3 had very low expression in brain tissue. Wild-type AAV6 (AAV6.1) expressed the fluorescent protein more efficiently than AAV2, while modified AAV6.2 and AAV6.3 had comparable expression efficiencies. Wild-type AAV9 (AAV9.1) had the highest overall expression efficiency, while the modified AAV9.2 showed a significant decrease in expression efficiency, reducing its value for in vivo applications. AAV9.3 also showed a slight decrease, but not significantly different from wild-type AAV9, thus remaining within the acceptable range. The significant differences in Figure 12 were analyzed using ANOVA with Dunnett post hoc analysis, comparing modified and wild-type AAVs pairwise. *P < 0.05.

[0210] As in previous studies, the histological data of this example show that a lot of AAV2 and AAV9 injected into the lateral ventricle leak into the periphery, resulting in high expression of AAV in the liver (Figures 13 and 14). Wild-type AAV9 (AAV9.1) is particularly highly expressed in the liver. AAV2.2, AAV6.2, and AAV9.2 obtained after inserting GRGDSP at the 453 / 454 / 455 sites can reduce the expression of AAV in the liver. On the other hand, after the 588 site is modified, the expression of AAV2.3 in the liver is higher than that of the corresponding wild-type AAV2, and the expression of AAV6.3 in the liver after the 588 site is modified is comparable to the expression level of the corresponding wild-type AAV6 in the liver, while the expression of AAV9.3 in the liver is lower than that of wild-type AAV9. The significant difference analysis method in Figure 14 was: ANOVA plus Dunnett post hoc comparison of the modified and wild-type AAVs, respectively. The significant difference analysis method was: ANOVA plus Dunnett post hoc comparison of the modified and wild-type AAVs, respectively. *P<0.05, ***P<0.001, ****P<0.0001.

[0211] This example further uses qPCR to systematically detect the expression distribution of AAV in various major peripheral tissues (Figures 15 and 16). Similar to the above histological data, this example again shows from the DNA and RNA levels that the modified AAV obtained by inserting GRGDSP at the 453 / 454 / 455 sites can effectively reduce the "leakage" of AAV injected into the lateral ventricle compared with the wild type. The significant difference analysis method in Figures 15 and 16: ANOVA plus Dunnett post hoc compared the modified and wild type AAVs respectively, *P<0.05, **P<0.01, ***P<0.001.

[0212] In summary, inserting the GRGDSP short peptide into the 453 or 454 sites of AAV2 and AAV6 can enhance the affinity of the corresponding AAV for brain tissue, effectively reduce the "off-target" infection of peripheral tissues, and significantly improve the targeting of brain tissue. Inserting the GRGDSP short peptide into the 588 site of AAV9 (AAV9.3), although the expression in brain tissue is slightly lower than that of wild-type AAV9, there is no significant difference with wild-type AAV9. Considering that wild-type AAV9 has the highest overall expression efficiency in brain tissue compared with other wild-types, AAV9.3 is still within the usable range, and since the expression of AAV9.3 in the liver is lower than that of wild-type AAV9, the "leakage" of wild-type AAV9 can be reduced, so AAV9.3 can also be used as an ideal vector.

[0213] Example 4: In vitro detection of changes in protein expression capacity before and after AAV capsid modification by qPCR (transcription level) and Western blot (protein level)

[0214] The experimental results of Examples 2-3 above show that the ability of AAV6.2 and AAV9.2 to mediate target protein expression in cell lines in vitro (for example, by qualitative experiments to count RFP-positive cells) and liver tropism after modification are better than before modification. Therefore, AAV6.2 and AAV9.2 were selected as examples for further study in this Example 4, and the ability of AAV6.1, AAV6.2; AAV9.1, and AAV9.2 to infect target cells and express target proteins was relatively quantitatively detected by qPCR and WB.

[0215] Experimental methods:

[0216] AAV virus packaging and titer determination: AAV virus packaging was carried out according to the commonly used three-plasmid transfection method. RC plasmids (same as in Example 1, specifically RC6, RC6.2, RC9 and RC9.2 in Example 1), Helper plasmids and pAAV-CAG-EGFP plasmids were chemically transfected into HEK293 cells. AAV virus particles were separated and purified from HEK293T cells using an iodixanol concentration gradient. The titer of AAV was determined by the commonly used qPCR method. All AAVs use the CAG universal promoter and are used to express enhanced green fluorescent protein (EGFP). The packaging and titer determination of AAV viruses were completed by Shandong Weizhen Biotechnology Co., Ltd. Weizhen Biotechnology Co., Ltd. provides reagents and equipment except for RC plasmids.

[0217] The packaged virus titers are as follows:

[0218] Cell recovery

[0219] HEK293 (kindly provided by Zhejiang Xinma Biopharmaceutical Co., Ltd.) and BT474 (kindly provided by Zhejiang Xinma Biopharmaceutical Co., Ltd.) cells were taken out of the liquid nitrogen tank and revived in a culture dish, and cultured to the third generation under appropriate conditions.

[0220] Cell plating and viral infection

[0221] 1) Take logarithmically growing cells and add 1×10 5 10,000 cells per well of a 24-well plate; 10,000 cells per well of a 96-well plate;

[0222] 2) When the cell confluence reaches 70-80%, virus infection is performed. 2-4 hours before infection, the medium is changed and 1 ml of culture medium is added to each well. 4×10 10 vg of virus (N=3), 10 10 vg virus (N=3).

[0223] RNA extraction

[0224] Cellular RNA was extracted using the RNA extraction kit of Yisheng Biotechnology (Shanghai) Co., Ltd., and the concentration was immediately determined and reverse transcribed.

[0225] RNA reverse transcription

[0226] RNA was reverse transcribed into cDNA using a reverse transcription kit from Beijing Quanshijin Biotechnology Co., Ltd.

[0227] qPCR

[0228] 1. Primer design and synthesis: Primers were designed using Primer 5 and delivered to GenScript for synthesis.

[0229] 2. Primer sequences are shown below. After obtaining the primers, add DEPC water according to the instructions, vortex thoroughly, and store at -20°C.

[0230] hActin-F:CATGTACGTTGCTATCCAGGC (SEQ ID NO: 24)

[0231] hActin-R: CTCCTTAATGTCACGCACGAT (SEQ ID NO: 25)

[0232] EGFP-F: GACCACTACCAGCAGAACAC (SEQ ID NO: 26)

[0233] EGFP-R: GAACTCCAGCAGGACCATG (SEQ ID NO: 27)

[0234] qPCR reaction system and conditions:

[0235] The experiments were performed using a qPCR kit from Beijing Quanshijin Biotechnology Co., Ltd.

[0236] Configuration system:

[0237] 2×Green qPCR SuperMix 10μl

[0238] Upstream primer (10mM) 0.4μl

[0239] Downstream primer (10mM) 0.4μl

[0240] Template cDNA 1 μl

[0241] ddH2O 8.2μl

[0242] After spotting, close the lid and centrifuge briefly to mix thoroughly and remove bubbles. Analyze on a real-time quantitative PCR instrument using the following reaction conditions: 94°C for 30 seconds, 94°C for 5 seconds, and 60°C for 30 seconds; Melt curve cycle number: 40. Data were analyzed using the delta-delta Ct method.

[0243] Western blot (WB)

[0244] (1) Preparation of cell protein samples

[0245] a. Prepare cell lysis buffer by adding 100 mM PMSF to RIPA cell lysis buffer at a volume ratio of RIPA:PMSF = 100:1 (Shanghai Beyotime Biotechnology Co., Ltd.) and store on ice. b. Wash cell samples at the corresponding time points three times with 4°C pre-chilled PBS buffer. c. Add 200 μl of RIPA lysis buffer to each well of a six-well plate. Gently shake the plate, place the plate in an ice box, and place the ice box on a shaker. Incubate for 10 minutes to fully lyse the cells. d. Gently pipette the cell lysis buffer until no obvious cell clumps remain. Transfer the solution to a 1.5 mL centrifuge tube and centrifuge at 12,000 rpm for 10 minutes at 4°C. Carefully aspirate 150 μl of the supernatant (the remainder will be used for BCA analysis) into a newly labeled 1.5 mL centrifuge tube. Add 50 μl of 4× SDS protein loading buffer and boil the sample in a metal bath at 100°C for 10 minutes. Store at -20°C for extended storage.

[0246] (2) Protein concentration determination

[0247] a. Carefully aspirate 20 μl of the above protein sample into a 96-well plate. b. Apply 0, 2, 4, 6, 8, 12, 16, and 20 μl of 5 mg / mL BSA protein standard to a 96-well plate and add PBS buffer to a final volume of 20 μl. c. Add working solution (BCA reagent: Cu reagent = 50:1, 200 μl / well) (Shanghai Beyotime Biotechnology Co., Ltd.). d. Incubate at 37°C in the dark for 30 min. Measure absorbance at 562 nm using a microplate reader, plot a standard curve, and calculate the corresponding protein sample concentrations.

[0248] (3) SDS-PAGE immunoblotting analysis

[0249] a. Electrophoresis conditions: Constant voltage 70V for 50 minutes, constant voltage 110V for 70 minutes. Observe bromophenol blue at the leading edge of the gel to confirm the end of electrophoresis. b. Transfer: Remove refrigerator-chilled 1× transfer buffer and soak the transfer apparatus. Activate the PVDF membrane with anhydrous methanol for 30 seconds. Place the transfer apparatus in the wet state in the following order: black side - metal mesh - three-layer filter paper - gel - PVDF membrane - three-layer filter paper - metal mesh - white side. Place the clips in the transfer chamber in the order (black on black, red on red). Fill the transfer chamber with transfer buffer up to the blotting mark. Transfer at 4°C, 200mA for 2 hours. c. After blocking and transferring, inspect the separating gel for excess marker residue. If no excess residue is present, completely immerse the PVDF membrane in a plastic box filled with 5% skim milk powder. Place the box on a shaker at low speed and incubate at room temperature for 1-2 hours. d. After the antibody incubation and blocking, briefly rinse the PVDF membrane with Ultrapure water. Cut the membrane according to the corresponding protein size and place the membrane into the compartment of the antibody incubation box. Add the corresponding primary antibody at a dilution of 1:1000. Place the antibody incubation box on a low-speed shaker and incubate at 4°C for 16-20 hours. After the primary antibody incubation, remove the primary antibody, rinse with 1× TBST, and incubate on a shaker at room temperature for 10 minutes (repeat three times). Add the secondary antibody (1:10,000), place the antibody incubation box on a low-speed shaker, incubate at room temperature for 1 hour, and discard the solution. Rinse with 1× TBST and incubate on a shaker at room temperature for 10 minutes (repeat three times). e. Development: Add ECL luminescent solution (solution A:solution B = 1:1), expose, save the image data, and perform grayscale analysis using ImageJ.

[0250] Experimental results and analysis:

[0251] The 24- and 6-well plate cell samples were lysed to extract RNA and protein, and the EGFP mRNA and protein levels were detected by relative quantitative qPCR and western blot (β-actin as an internal reference). The results are shown in Figures 17 to 20B. As shown in Figure 17, the results show that in HEK293 cells, all capsids mediated EGFP expression, and the EGFP level was significantly increased compared to the NC group (blank control group - no AAV infection). After the capsid was added with short peptides, the infection ability was significantly increased compared to before the modification (AAV6.2 increased 36.5 times compared to AAV6, and AAV9.2 increased 6.44 times compared to AAV9), and AAV6.2 was significantly better than AAV9.2 (20.8 times).

[0252] As shown in Figures 18A and 18B , the WB experimental results were consistent with the qPCR results. In HEK293 cells, the ability of the modified AAV to mediate EGFP protein expression was significantly improved compared with that before modification, and AAV6.2 was superior to AAV9.2.

[0253] As shown in Figure 19, in BT474 cells, the modified AAV6.2 has a stronger ability to infect BT474 cells (AAV6.2 is 4.4 times higher than AAV6), while AAV9 and AAV9.2 have lower abilities to infect BT474 cells, and there is no significant difference before and after modification.

[0254] As shown in Figures 20A and 20B , the WB experimental results were consistent with the qPCR results. The ability of the modified AAV6.2 to mediate EGFP protein expression was significantly improved compared to before modification, and no AAV9 and AAV9.2-mediated EGFP expression in BT474 cells was detected.

[0255] Therefore, the results of qPCR and WB experiments showed that AAV6.2 had stronger infection ability than before modification, and AAV6.2-mediated EGFP expression ability was better than AAV9.2 (in HEK293 and BT474 cells).

[0256] It should be noted that the results of this example, as demonstrated in Examples 2-3, can enhance the affinity of the corresponding AAV for brain tissue, effectively reduce "off-target" infection of peripheral tissues, and significantly improve targeting to brain tissue. Therefore, the low ability to infect human embryonic kidney HEK293T cells and human breast ductal carcinoma cell BT474 cells does not mean that they cannot be used as vectors targeting brain tissue.

[0257] Example 5: In vitro verification of the relationship between AAV6 and AAV6.2-mediated protein expression ability and infection time

[0258] Considering that the results of Example 4 show that the ability of the modified AAV6.2 to mediate the expression of the target protein in the cell line in vitro is significantly better than that before the modification (for example, by relative quantitative experiments to detect mRNA levels and protein levels), AAV6.2 is selected as an example for further exploration in this Example 5.

[0259] This example investigates the ability and advantages of modified capsids in mediating target protein expression. Gastric, breast, colon, prostate, and melanoma cancers often metastasize to the brain, so corresponding cell lines and brain tumor cell lines were selected for this experiment. This experiment used equal titers of AAV6 and AAV6.2 to infect cell lines of different origins. EGFP fluorescence intensity was measured using a microplate reader to quantify the ability of AAV to mediate target protein expression.

[0260] Experimental methods

[0261] Different cell lines (see Table 2, all purchased from Wuhan Punosai Life Science Co., Ltd.) were used to plate cells in 96-well plates. The number of cells per well was determined based on the cell characteristics. For cells with a doubling time of approximately 24 hours, the number of cells plated should be 5,000-10,000; for cells with a doubling time of approximately 84 hours or longer, the number of cells plated should be 20,000-30,000.

[0262] After the confluence reached 40-50%, viruses (AAV6-CAG-EGFP and AAV6.2-CAG-EGFP prepared in Example 4) were added.

[0263] The culture medium of the corresponding group was replaced with complete medium without virus (n=6) at the corresponding time points until 72 hours after infection. EGFP fluorescence intensity was measured by microplate reader. The infection time points were 0 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, and 72 hours.

[0264] Experimental results and analysis:

[0265] Table 2:

[0266] The experimental results are shown in Table 2 and Figures 21A to 21I. They demonstrate that both AAV6 and AAV6.2 can infect small cell lung cancer, neuroblastoma, glioma, glioblastoma, breast cancer, prostate cancer, malignant melanoma, and colon cancer cells, and that the modified capsids significantly enhance the expression of target proteins.

[0267] References

[0268] 1. Lawler, SE et al. "Genetic strategies for brain tumor therapy." Cancer gene therapy vol.13,3(2006):225-33.doi:10.1038 / sj.cgt.7700886

[0269] 2.Vance, Melisa, Mitchell, Angela, Samulski, Richard. "AAV Biology, Infectivity and Therapeutic Use from Bench to Clinic". Gene Therapy-Principles and Challenges, edited by Doaa Hashad, IntechOpen, 2015.10.5772 / 61988.

[0270] 3.Santiago-Ortiz,Jorge L,and David V Schaffer.“Adeno-associated virus(AAV)vectors in cancer gene therapy.”Journal of controlled release:official journal of the Controlled Release Society vol.240(2016):287-301.doi:10.1016 / j.jconrel.2016.01.001

[0271] 4.Büning,Hildegard,and Arun Srivastava.“Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors.”Molecular therapy.Methods&clinical development vol.12 248-265.26 Jan.2019,doi:10.1016 / j.omtm.2019.01.008

[0272] 5.Davidson,B L et al.“Recombinant adeno-associated virus type 2,4,and 5 vectors:transduction of variant cell types and regions in the mammalian central nervous system.”Proceedings of the National Academy of Sciences of the United States of America vol.97,7(2000):3428-32.doi:10.1073 / pnas.97.7.3428

[0273] 6.Dirren,Elisabeth et al.“Intracerebroventricular injection of adeno-associated virus 6and 9vectors for cell type-specific transgene expression in the spinal cord.”Human gene therapy vol.25,2(2014):109-20.doi:10.1089 / hum.2013.021

[0274] 7.Girod,A et al.“Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.”Nature medicine vol.5,9(1999):1052-6.doi:10.1038 / 12491

[0275] 8.Shi,Wenfang,and Jeffrey S Bartlett.“RGD inclusion in VP3 provides adeno-associated virus type 2(AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism.”Molecular therapy:the journal of the American Society of Gene Therapy vol.7,4(2003):515-25.doi:10.1016 / s1525-0016(03)00042-x

[0276] 9.Boucas,Jorge et al.“Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations.”The journal of gene medicine vol.11,12(2009):1103-13.doi:10.1002 / jgm.1392

Claims

1. An adeno-associated virus capsid protein, comprising a targeting peptide, wherein the targeting peptide comprises one or more of the following sequences: (i) the amino acid sequence shown in SEQ ID NO: 23; (ii) an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 23, and that has or partially has the function of the amino acid sequence of SEQ ID NO: 23; (iii) an amino acid sequence in which one or more amino acid residues are added, substituted, deleted or inserted into the amino acid sequence of SEQ ID NO: 23, and which has or partially has the function of the amino acid sequence of SEQ ID NO: 23; or, (iv) an amino acid sequence encoded by a nucleotide sequence, which hybridizes with a polynucleotide sequence encoding the amino acid sequence as shown in SEQ ID NO: 23 under stringent conditions, and the amino acid sequence has or partially has the function of the amino acid sequence as shown in SEQ ID NO: 23, and the stringent conditions are medium stringency conditions, medium-high stringency conditions, high stringency conditions or very high stringency conditions.

2. The adeno-associated virus capsid protein according to claim 1, in, The adeno-associated virus is selected from one or more of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, rh.10, rh.39, rh.43 and rh.74; Preferably, the adeno-associated virus is selected from one or more of AAV2, AAV6 and AAV9.

3. The adeno-associated virus capsid protein according to claim 1 or 2, in, AAV2 comprises AAV2 VP1, AAV2 VP2 and / or AAV2 VP3; and / or, AAV6 comprises AAV6 VP1, AAV6 VP2 and / or AAV6 VP3; and / or, AAV9 includes AAV9 VP1, AAV9 VP2 and / or AAV9 VP3.

4. The adeno-associated virus capsid protein according to claim 3, in, The targeting peptide is inserted at the amino acid 453 position and / or the amino acid 588 position of AAV2 VP1, AAV2 VP2 and / or AAV2 VP3; and / or, The targeting peptide is inserted at the amino acid 454 position and / or the amino acid 588 position of AAV6 VP1, AAV6 VP2 and / or AAV6 VP3; and / or, The targeting peptide is inserted at the amino acid 455 position and / or the amino acid 588 position of AAV9 VP1, AAV9 VP2 and / or AAV9 VP3.

5. The adeno-associated virus capsid protein according to claim 3, in, The targeting peptide is inserted at position 453 of amino acid 453 of AAV2 VP1, AAV2 VP2 and / or AAV2 VP3; and / or, The targeting peptide is inserted at position 454 of amino acid of AAV6 VP1, AAV6 VP2 and / or AAV6 VP3; and / or, The targeting peptide is inserted at position 588 of amino acid of AAV9 VP1, AAV9 VP2 and / or AAV9 VP3. A polynucleotide encoding the adeno-associated virus capsid protein according to any one of claims 1 to 5. 7 . An adeno-associated virus comprising the adeno-associated virus capsid protein according to any one of claims 1 to 5 .

8. The adeno-associated virus according to claim 7, further comprising a transgene; Optionally, the transgene is a therapeutic transgene, a preventive transgene or a diagnostic transgene.

9. A transgene delivery vector comprising the adeno-associated virus according to claim 7 or 8.

10. A pharmaceutical composition comprising: (a) an adeno-associated virus according to claim 7 or 8, or a transgene delivery vector according to claim 9; and, optionally, (b) a pharmaceutically acceptable carrier.

11. Use of the adeno-associated virus according to claim 7 or 8, the transgene delivery vector according to claim 9, or the pharmaceutical composition according to claim 10 in the preparation of an agent for delivering a transgene to a cell.

12. The use according to claim 11, in, The cells are from a subject; Preferably, the subject is a mammalian subject; More preferably, the subject is a human.

13. The use according to claim 11 or 12, in, The cells are from brain tissue.

14. The use according to claim 12 or 13, in, The subject suffers from a brain disease.

15. The use according to any one of claims 11 to 14, in, The adeno-associated virus, the transgene delivery vector, or the pharmaceutical composition is administered to the subject via one or more of intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular, intracerebrospinal fluid, brain tissue, or intratumoral administration; Preferably, administration to the subject is one or more of intravenous, intraarterial, intracerebrospinal fluid, intracerebral tissue, or intratumoral.

16. Use of the adeno-associated virus according to claim 7 or 8, the transgenic delivery vector according to claim 9, or the pharmaceutical composition according to claim 10 in the preparation of a drug for treating a disease; Preferably, the disease comprises a brain disease.

Citation Information

Patent Citations

  • Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides

    US4522811A

  • Tgfp-cap peptide and its uses

    CN101687935A

  • Tropism-modified recombinant viral vectors and uses thereof for the targeted introduction of genetic material into human cells

    CN110799524A

  • Engineered muscle targeting compositions

    CN115175991A

  • Adeno-associated virus mutant and application thereof

    CN116041443A

Cited By

  • Her2 antibody capable of being expressed by adeno-associated virus

    CN120082564A